SWOG clinical trial number
CTSU/E2112

A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in patients with Hormone Receptor-Positive Advanced Breast Cancer.

Closed
Phase
Abbreviated Title
Randomized Ph III of ET +/- Entinostat in HR+ Advanced BC
Activated
03/29/2014
Closed
10/17/2018
Participants
CTSU

Research committees

Breast Cancer

Treatment

Entinostat

Publication Information Expand/Collapse

2021

E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN Cancer Research Group

RM Connolly;F Zhao;K Miller;M Lee;R Piekarz;K Smith;U Brown-Glaberman;B Faller;AA Onitilo;M Burkard;GT Budd;E Levine;M Royce;P Kaufman;A Thomas;J Trepel;A Wolff;J Sparano Journal of Clinical Oncology, Oct 1;39(28):3171-3181

PMid: PMID34357781 | PMC number: PMC8478386

2020

E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN Cancer Research Group

R Connolly;F Zhao;K Miller;M Lee;R Piekarz;K Smith;U Brown-Glaberman;J Winn;A Lyss;A Onitilo;M Burkard;G Budd;E Levine;M Royce;P Kaufman;A Thomas;J Trepel;A Wolff;J Sparano San Antonio Breast Cancer Symposium (December 8-12, 2020, virtual), oral slide presentation, abst. GS402

Other Clinical Trials

SWOG Clinical Trial Number
CTSU-A012301

LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
Research Committee(s)
Breast Cancer
Activated
02/05/2025
Open
Phase
SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
21%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
31%
Open
Phase